Becton, Dickinson and Company $BDX Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 64.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,303 shares of the medical instruments supplier’s stock after selling 83,188 shares during the quarter. Teacher Retirement System of Texas’ holdings in Becton, Dickinson and Company were worth $7,976,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $3,458,000. Cacti Asset Management LLC raised its stake in shares of Becton, Dickinson and Company by 0.8% in the 2nd quarter. Cacti Asset Management LLC now owns 180,271 shares of the medical instruments supplier’s stock valued at $30,801,000 after purchasing an additional 1,500 shares in the last quarter. Baker Tilly Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 25.4% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 6,898 shares of the medical instruments supplier’s stock valued at $1,188,000 after purchasing an additional 1,399 shares in the last quarter. Finally, Northside Capital Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $7,939,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.5%

Shares of NYSE:BDX opened at $181.49 on Thursday. The stock has a market capitalization of $52.02 billion, a price-to-earnings ratio of 32.64, a PEG ratio of 1.44 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a 50 day moving average price of $189.14 and a 200 day moving average price of $183.39.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDX. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 1,895 shares of company stock valued at $358,995. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.